Evidence map›Paper›PMID 37465667›Full record

ArticleFrontiers in immunology2023

Immunogenomic profile at baseline predicts host susceptibility to clinical malaria.

Gillian Mbambo, Ankit Dwivedi, Olukemi O Ifeonu, James B Munro, Biraj Shrestha, Robin E Bromley, Theresa Hodges, Ricky S Adkins, Bourema Kouriba, Issa Diarra and 13 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 3 institutions in 3 countries.

Gillian MbamboInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Ankit DwivediInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Olukemi O IfeonuInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
James B MunroInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Biraj ShresthaCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Robin E BromleyInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Theresa HodgesInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Ricky S AdkinsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Bourema KouribaMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Issa DiarraMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Amadou NiangalyMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Abdoulaye K KoneMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Drissa CoulibalyMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Karim TraoreMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Amagana DoloMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Mahamadou A TheraMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Matthew B LaurensCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Ogobara K DoumboMalaria Research and Training Center, International Centers for Excellence in Research (NIH), University of Science Techniques and Technologies of Bamako, Bamako, Mali.
Christopher V PloweCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Andrea A BerryCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Mark TravassosCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Kirsten E LykeCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Joana C SilvaInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
University of Maryland, Baltimore · USUniversité des Sciences, des Techniques et des Technologies de Bamako · MLUniversidade Nova de Lisboa · PT

Funding

Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WHITE, OWEN R · 2014 to 2023
$36.5M
EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Safety, Immunogenicity and Efficacy of VaccineU19AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2005 to 2009
$4.7M
Genetic diversity and protective immunity to malaria infection and diseaseU01AI065683 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2010 to 2014
$3.0M
MALARIA RESEARCH TRAINING IN MALID43TW001589 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2000 to 2015
$2.8M
Malaria:Clinical Research and Trial Preparation Sites-26685346N01AI085346 · NIAID · Univ Maryland · 1998 to 2004
$2.8M
Protein microarray antibody responses to P. falciparum in a human challenge modelK23AI125720 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI BERRY, ANDREA · 2017 to 2021
$915k
FIC NIH HHS D43 TW001589NIAID NIH HHS K23 AI125720NIAID NIH HHS N01 AI085346NIAID NIH HHS U01 AI065683NIAID NIH HHS U19 AI065683NIAID NIH HHS U19 AI110820NIGMS NIH HHS R25 GM055036
6 · The paper itself

Abstract

Introduction: Host gene and protein expression impact susceptibility to clinical malaria, but the balance of immune cell populations, cytokines and genes that contributes to protection, remains incompletely understood. Little is known about the determinants of host susceptibility to clinical malaria at a time when acquired immunity is developing. Methods: We analyzed peripheral blood mononuclear cells (PBMCs) collected from children who differed in susceptibility to clinical malaria, all from a small town in Mali. PBMCs were collected from children aged 4-6 years at the start, peak and end of the malaria season. We characterized the immune cell composition and cytokine secretion for a subset of 20 children per timepoint (10 children with no symptomatic malaria age-matched to 10 children with >2 symptomatic malarial illnesses), and gene expression patterns for six children (three per cohort) per timepoint. Results: We observed differences between the two groups of children in the expression of genes related to cell death and inflammation; in particular, inflammatory genes such as CXCL10 and STAT1 and apoptotic genes such as XAF1 were upregulated in susceptible children before the transmission season began. We also noted higher frequency of HLA-DR+ CD4 T cells in protected children during the peak of the malaria season and comparable levels cytokine secretion after stimulation with malaria schizonts across all three time points. Conclusion: This study highlights the importance of baseline immune signatures in determining disease outcome. Our data suggests that differences in apoptotic and inflammatory gene expression patterns can serve as predictive markers of susceptibility to clinical malaria.

Indexed as

MalariaMalaria, FalciparumAdaptive ImmunityChildCytokinesHumansLeukocytes, MononuclearCytokinesbaseline immunityhuman parasite immunologyimmunoinformatic analysismalaria immunitymalaria susceptibilitymass cytometrýRNA sequencing

Identifiers

PMID37465667
PMCPMC10351378
OpenAlexW4382940228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.